Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (6925)	7/23/1999 5:57:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 9719

Hey, I said over here among my stocks, not over where you are. <g>. (Although CBST which I own a little of has seemed pretty frothy the last few days.) BTW, I just started a new thread "Biotechs vs. Shorts" techstocks.com Maybe V1 would like to come and talk about Avalon/CLTR. <g> (Have to drum up business somehow). Peter

To: biowa who wrote (6925)	8/11/1999 3:04:00 PM
From: squetch	Read Replies (1) \| Respond to of 9719

Sorry, but I found the name of the testing center funny. Cream shows promise for female sex problems - firm WASHINGTON, Aug 6 (Reuters) - A drug originally formulated to help impotent men may work as a cream for women with sexual disorders, a small New Jersey company said on Friday. The cream, which uses the drug alprostadil, was safe and helped a very small group of women enjoy sex, NexMed Inc. (OTC BB:NEXM - news) said in a statement. The cream, known as Femprox, was tested on eight women at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. ''The study showed statistically significant, dose-related improvements in arousal, lubrication, engorgement, pleasure, and relaxation,'' the company said in its statement. ''The Femprox product is intended to improve vaginal secretions and thereby increase sexual arousal and pleasure during intercourse.'' Various examinations were used to measure how well the drug worked in the women, none of whom had gone through menopause. ''The results from this Phase I clinical trial are very encouraging and indicate that Femprox has the potential to become a safe and efficacious treatment for women with sexual dysfunction,'' Dr. James Yeager, vice president for research and development at NexMed, said in a statement. He said the company planned to test its product in more women in Phase II clinical trials. University of Chicago researchers said in February that 43 percent of women and 30 percent of men in the United States suffer from sexual dysfunction. Much of it comes from reduced blood flow to the genital area, researchers say -- both for men and for women. The problem is most common in women past menopause, who frequently complain that intercourse is difficult or painful because of a lack of feeling and lubrication. The best-selling drug Viagra, made by Pfizer (NYSE:PFE - news), increases blood flow to the region but it is taken in the form of a pill, thus affecting the entire body and causing sometimes fatal side-effects. The race is on to develop a cream that will work as well without the side-effects. With an eye to this, NexMed is developing Alprox-TD, an alprostadil cream for men. Mountain View, California-based Vivus Inc. (Nasdaq:VVUS - news) has an alprostadil pellet, called Muse, that men can insert into the urethra to treat impotence. The company is also working on a cream form of the drug.